POINT Biopharma Global Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2020 to 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
POINT Biopharma Global Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2020 to 2022.
- POINT Biopharma Global Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2023 was -$23.9M, a 0.3% decline year-over-year.
- POINT Biopharma Global Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2023 was $127M.
- POINT Biopharma Global Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $130M.
- POINT Biopharma Global Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$45.6M, a 243% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)